Dianthus Therapeutics Reports Interim Results from CAPTIVATE Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 19 hours ago
0mins
Should l Buy DNTH?
Source: NASDAQ.COM
- Clinical Trial Update: Dianthus Therapeutics hosted a conference call on March 9, 2026, to discuss interim responder analysis results from its Phase 3 CAPTIVATE trial evaluating Claseprubart for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), demonstrating rapid, sustained, and clinically meaningful improvements in generalized myasthenia gravis (gMG) patients in earlier studies.
- Strong Financial Position: As of the end of 2025, Dianthus reported approximately $514 million in cash reserves, providing a runway into 2028 to support multiple clinical milestones, including the Phase 3 initiation of gMG and additional readouts in multifocal motor neuropathy (MMN), showcasing the company's robust R&D potential.
- Market Performance: Dianthus' stock has traded between $13.37 and $65.50 over the past year, closing at $65.20 on March 6, 2026, up 6.14% from the previous day, and reaching a new 52-week high during overnight trading, reflecting positive investor sentiment regarding its clinical advancements.
- Drug Potential Assessment: Claseprubart is considered to have
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DNTH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DNTH
Wall Street analysts forecast DNTH stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 65.200
Low
46.00
Averages
77.00
High
125.00
Current: 65.200
Low
46.00
Averages
77.00
High
125.00
About DNTH
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company engaged in designing and delivering monoclonal antibodies with improved selectivity and potency. The Company is focused on developing complement therapeutics for patients living with severe autoimmune and inflammatory diseases. Its advanced product candidate, DNTH103, is a clinical-stage, highly potent, selective and fully human monoclonal immunoglobulin G4 with picomolar binding affinity that is designed to selectively bind only to the active form of C1s. DNTH103 is engineered with YTE half-life extension technology, a specific three amino acid change in the Fc domain, and has a pharmacokinetic (PK) profile designed to support less frequent, lower dose, self-administration as a convenient S.C. injection. It is conducting three mid- to late-stage clinical trials with DNTH103 in generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Multifocal Motor Neuropathy (MMN).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Dianthus Therapeutics Launches $400 Million Public Offering
- Offering Size: Dianthus Therapeutics has announced the commencement of a $400 million public offering of common stock, with plans to offer pre-funded warrants to certain investors, indicating the company's proactive approach to capital markets.
- Underwriters' Option: The company expects to grant underwriters a 30-day option to purchase up to an additional $60 million of common stock at the public offering price, a strategy that may enhance demand for its shares in the market.
- Use of Proceeds: The net proceeds from this offering are intended to support clinical and preclinical development, commercial readiness activities, and general corporate purposes, underscoring the company's strategic focus on R&D and market preparedness.
- Stock Price Reaction: Following the announcement of the offering, Dianthus Therapeutics' stock price fell 3.46% in after-hours trading to $76.69, reflecting a cautious market sentiment regarding the offering.
See More
Liquidia and Dianthus See Active Options Trading
- Liquidia Options Volume: Liquidia Corp (Ticker: LQDA) experienced an options trading volume of 9,692 contracts today, equating to approximately 969,200 shares, which represents about 48.1% of its average daily trading volume of 2 million shares over the past month, indicating heightened market interest in its future performance.
- High Call Option Activity: Among LQDA options, the $47.50 strike call option expiring on January 21, 2028, has seen particularly high activity with 3,100 contracts traded today, representing around 310,000 underlying shares, suggesting increased investor expectations for a price rise.
- Dianthus Options Trading: Dianthus Therapeutics Inc (Ticker: DNTH) recorded an options trading volume of 3,379 contracts today, equivalent to approximately 337,900 shares, which is about 48% of its average daily trading volume of 704,415 shares over the past month, reflecting market interest in its potential volatility.
- High Put Option Activity: The $50 strike put option for DNTH, expiring on March 20, 2026, has seen 1,659 contracts traded today, representing approximately 165,900 underlying shares, indicating investor concern regarding potential downside risks.
See More
Dianthus Therapeutics Early Decision Boosts Stock Surge
- Early Decision Impact: Dianthus Therapeutics announced an early 'go' decision for its experimental drug claseprubart in the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) program, leading to a 19% surge in stock price on Monday, reflecting heightened market optimism.
- Clinical Trial Results: In part A of the trial, more than 20 responders were confirmed out of 40 participants, achieving a response rate of 50% or greater, with no serious infections or discontinuations observed, indicating both safety and efficacy of the drug.
- Analyst Rating Upgrades: Truist raised Dianthus's price target from $63 to $110, while H.C. Wainwright increased its target from $47 to $130, also boosting the probability of launch for claseprubart from 26% to 35%, showcasing confidence in the drug's prospects.
- Market Sentiment Shift: On Stocktwits, retail sentiment around DNTH stock jumped from 'bullish' to 'extremely bullish' in the past 24 hours, with message volume increasing from 'high' to 'extremely high', indicating strong investor interest in the company.
See More
Relmada Therapeutics Shares Surge 40.8% on Promising Trial Data
- Market Decline: U.S. stocks fell broadly on Monday, with the Dow Jones index dropping around 650 points, indicating investor concerns about economic outlook which may impact consumer spending and overall market confidence.
- Relmada Stock Surge: Shares of Relmada Therapeutics Inc. soared 40.8% to $6.27 during Monday's session, driven by the release of promising interim data from its Phase 2 trial of NDV-01 for treating non-muscle invasive bladder cancer.
- Clinical Trial Results: The 12-month interim data revealed a complete response rate of 76%, with an impressive 80% in the BCG-unresponsive patient population, providing strong support for Relmada's treatment approach and potentially enhancing market acceptance.
- Positive Market Reaction: The favorable feedback from clinical data has led to optimistic investor sentiment regarding Relmada's future prospects, not only boosting the company's stock price but also likely attracting more investor interest in its ongoing research and development efforts.
See More
Dianthus Achieves Key Milestones in CIDP Trial
- Trial Progress: Dianthus confirmed achieving the GO criteria with 20 confirmed responders in the open-label Part A of the trial, with fewer than 40 planned participants, indicating preliminary efficacy and potential market prospects for the treatment.
- Patient Recruitment Plan: The company expects to enroll up to 256 patients in Part A and randomize 128 patients in Part B, aiming to optimize trial design and enhance the reliability of clinical data.
- Strong Financial Position: As of December 31, 2025, Dianthus has $514.4 million in cash, providing runway into 2028, which bolsters investor confidence in its long-term growth potential.
- Robust Stock Performance: Dianthus shares have increased by 167.87% over the past 12 months, currently trading at $80.06, reflecting strong market performance and positive investor sentiment.
See More
Dianthus Therapeutics Reports Q4 Earnings Miss
- Earnings Report Disappointment: Dianthus Therapeutics reported a Q4 GAAP EPS of -$1.43, missing expectations by $0.34, indicating ongoing challenges in profitability.
- Significant Revenue Decline: The company’s Q4 revenue of $0.28 million represents a 78.9% year-over-year decrease, falling short of the expected $0.17 million, reflecting weak market demand and insufficient sales strategies.
- Cash Position: As of December 31, 2025, the company holds $514.4 million in cash, cash equivalents, and investments, projected to sustain operations into 2028, indicating a degree of financial stability.
- Future Outlook: Despite current financial setbacks, the company is actively participating in industry conferences, such as the 2026 Guggenheim Securities Emerging Outlook: Biotech Summit, aiming to boost market confidence and attract investor interest.
See More
Dianthus Therapeutics Launches $400 Million Public Offering
- Offering Size: Dianthus Therapeutics has announced the commencement of a $400 million public offering of common stock, with plans to offer pre-funded warrants to certain investors, indicating the company's proactive approach to capital markets.
- Underwriters' Option: The company expects to grant underwriters a 30-day option to purchase up to an additional $60 million of common stock at the public offering price, a strategy that may enhance demand for its shares in the market.
- Use of Proceeds: The net proceeds from this offering are intended to support clinical and preclinical development, commercial readiness activities, and general corporate purposes, underscoring the company's strategic focus on R&D and market preparedness.
- Stock Price Reaction: Following the announcement of the offering, Dianthus Therapeutics' stock price fell 3.46% in after-hours trading to $76.69, reflecting a cautious market sentiment regarding the offering.
See More
Liquidia and Dianthus See Active Options Trading
- Liquidia Options Volume: Liquidia Corp (Ticker: LQDA) experienced an options trading volume of 9,692 contracts today, equating to approximately 969,200 shares, which represents about 48.1% of its average daily trading volume of 2 million shares over the past month, indicating heightened market interest in its future performance.
- High Call Option Activity: Among LQDA options, the $47.50 strike call option expiring on January 21, 2028, has seen particularly high activity with 3,100 contracts traded today, representing around 310,000 underlying shares, suggesting increased investor expectations for a price rise.
- Dianthus Options Trading: Dianthus Therapeutics Inc (Ticker: DNTH) recorded an options trading volume of 3,379 contracts today, equivalent to approximately 337,900 shares, which is about 48% of its average daily trading volume of 704,415 shares over the past month, reflecting market interest in its potential volatility.
- High Put Option Activity: The $50 strike put option for DNTH, expiring on March 20, 2026, has seen 1,659 contracts traded today, representing approximately 165,900 underlying shares, indicating investor concern regarding potential downside risks.
See More
Dianthus Therapeutics Early Decision Boosts Stock Surge
- Early Decision Impact: Dianthus Therapeutics announced an early 'go' decision for its experimental drug claseprubart in the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) program, leading to a 19% surge in stock price on Monday, reflecting heightened market optimism.
- Clinical Trial Results: In part A of the trial, more than 20 responders were confirmed out of 40 participants, achieving a response rate of 50% or greater, with no serious infections or discontinuations observed, indicating both safety and efficacy of the drug.
- Analyst Rating Upgrades: Truist raised Dianthus's price target from $63 to $110, while H.C. Wainwright increased its target from $47 to $130, also boosting the probability of launch for claseprubart from 26% to 35%, showcasing confidence in the drug's prospects.
- Market Sentiment Shift: On Stocktwits, retail sentiment around DNTH stock jumped from 'bullish' to 'extremely bullish' in the past 24 hours, with message volume increasing from 'high' to 'extremely high', indicating strong investor interest in the company.
See More
Relmada Therapeutics Shares Surge 40.8% on Promising Trial Data
- Market Decline: U.S. stocks fell broadly on Monday, with the Dow Jones index dropping around 650 points, indicating investor concerns about economic outlook which may impact consumer spending and overall market confidence.
- Relmada Stock Surge: Shares of Relmada Therapeutics Inc. soared 40.8% to $6.27 during Monday's session, driven by the release of promising interim data from its Phase 2 trial of NDV-01 for treating non-muscle invasive bladder cancer.
- Clinical Trial Results: The 12-month interim data revealed a complete response rate of 76%, with an impressive 80% in the BCG-unresponsive patient population, providing strong support for Relmada's treatment approach and potentially enhancing market acceptance.
- Positive Market Reaction: The favorable feedback from clinical data has led to optimistic investor sentiment regarding Relmada's future prospects, not only boosting the company's stock price but also likely attracting more investor interest in its ongoing research and development efforts.
See More
Dianthus Achieves Key Milestones in CIDP Trial
- Trial Progress: Dianthus confirmed achieving the GO criteria with 20 confirmed responders in the open-label Part A of the trial, with fewer than 40 planned participants, indicating preliminary efficacy and potential market prospects for the treatment.
- Patient Recruitment Plan: The company expects to enroll up to 256 patients in Part A and randomize 128 patients in Part B, aiming to optimize trial design and enhance the reliability of clinical data.
- Strong Financial Position: As of December 31, 2025, Dianthus has $514.4 million in cash, providing runway into 2028, which bolsters investor confidence in its long-term growth potential.
- Robust Stock Performance: Dianthus shares have increased by 167.87% over the past 12 months, currently trading at $80.06, reflecting strong market performance and positive investor sentiment.
See More
Dianthus Therapeutics Reports Q4 Earnings Miss
- Earnings Report Disappointment: Dianthus Therapeutics reported a Q4 GAAP EPS of -$1.43, missing expectations by $0.34, indicating ongoing challenges in profitability.
- Significant Revenue Decline: The company’s Q4 revenue of $0.28 million represents a 78.9% year-over-year decrease, falling short of the expected $0.17 million, reflecting weak market demand and insufficient sales strategies.
- Cash Position: As of December 31, 2025, the company holds $514.4 million in cash, cash equivalents, and investments, projected to sustain operations into 2028, indicating a degree of financial stability.
- Future Outlook: Despite current financial setbacks, the company is actively participating in industry conferences, such as the 2026 Guggenheim Securities Emerging Outlook: Biotech Summit, aiming to boost market confidence and attract investor interest.
See More
